All In Biotech

Drug Trial Radar · NCT04428333

Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination With Pembrolizumab and 5FU-Platinum Chemotherapy Versus Placebo in Combination With Pembrolizumab Plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Oct 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 117 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

117

Actual

Start

Aug 12, 2020

Primary completion

Apr 27, 2021

Study completion Sep 19, 2023

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Jun 11, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate if the addition of GSK3359609 to pembrolizumab in combination with 5FU-platinum based chemotherapy improves the efficacy of the pembrolizumab combination with 5FU-platinum based chemotherapy in participants with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). This randomized, double-blinded, Phase II/III study will compare the combination of GSK3359609 with pembrolizumab and 5FU-platinum chemotherapy to placebo in combination with pembrolizumab and 5FU-platinum chemotherapy in participants with recurrent or metastatic HNSCC of the oral cavity, oropharynx, hypopharynx or larynx.

Conditions

  • Neoplasms, Head and Neck

Interventions

  • FeladilimabDrug

    Humanized anti-inducible T cell co-stimulatory receptor (ICOS) immunoglobulin G4 (IgG4) monoclonal antibody (mAb)

  • PembrolizumabDrug

    Humanized anti- programmed cell death receptor1 (anti-PD-1) IgG4 mAb

  • PlaceboDrug

    Sterile normal saline

  • Platinum based chemotherapyDrug

    Cisplatin/carboplatin

  • Fluorouracil (5FU)Drug

    5-fluorouracil

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS) in mITT PopulationTime frame: Up to approximately 7 months
  2. OS in Programmed Death Receptor-ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 PopulationTime frame: Up to approximately 7 months
  3. Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 in mITT PopulationTime frame: Up to approximately 7 months

Locations

71 sites in 19 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Duarte, California

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Oro Verde Entre RIos, Argentina

  • GSK Investigational Site

    Rosario, Argentina

  • GSK Investigational Site

    San Miguel de Tucumán, Argentina

  • GSK Investigational Site

    Blacktown, Australia

  • GSK Investigational Site

    Heidelberg, Australia

  • GSK Investigational Site

    Melbourne, Australia

  • GSK Investigational Site

    Woolangabba, Australia

  • GSK Investigational Site

    Brussels, Belgium

  • GSK Investigational Site

    Edegem, Belgium

  • GSK Investigational Site

    Curitiba, Brazil

  • GSK Investigational Site

    São Paulo, Brazil

  • GSK Investigational Site

    Vitória, Brazil

  • GSK Investigational Site

    Edmonton, Alberta, Canada

  • GSK Investigational Site

    Hamilton, Ontario, Canada

  • GSK Investigational Site

    London, Ontario, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Montreal, Quebec, Canada

  • GSK Investigational Site

    Copenhagen, Denmark

  • GSK Investigational Site

    Bordeaux, France

  • GSK Investigational Site

    Lyon, France

  • GSK Investigational Site

    Paris, France

  • GSK Investigational Site

    Poitiers, France

  • GSK Investigational Site

    Strasbourg, France

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Hanover, Germany

  • GSK Investigational Site

    Leipzig, Germany

  • GSK Investigational Site

    Ulm, Germany

  • GSK Investigational Site

    Dublin, Ireland

  • GSK Investigational Site

    Brescia, Italy

  • GSK Investigational Site

    Florence, Italy

  • GSK Investigational Site

    Milan, Italy

  • GSK Investigational Site

    Naples, Italy

  • GSK Investigational Site

    Roma, Italy

  • GSK Investigational Site

    Savona, Italy

  • GSK Investigational Site

    Osaka, Japan

  • GSK Investigational Site

    Osaka, Japan

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.